Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

IDENTIFICATION OF EXPRESSION PROFILES DEFINING DISTINCT PROGNOSTIC SUBSETS OF RADIOACTIVE-IODINE REFRACTORY DIFFERENTIATED THYROID CANCER FROM THE DECISION TRIAL.

Capdevila J, Matos I, Mancuso FM, Iglesias C, Nuciforo P, Zafon C, Palmer HG, Ogbah Z, Muinos L, Hernando J, Villacampa G, Peña CE, Tabernero J, Brose MS, Schlumberger M, Vivancos A.

Mol Cancer Ther. 2019 Sep 20. pii: molcanther.0211.2019. doi: 10.1158/1535-7163.MCT-19-0211. [Epub ahead of print]

PMID:
31540966
2.

Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer.

Serna G, Ruiz-Pace F, Cecchi F, Fasani R, Jimenez J, Thyparambil S, Landolfi S, Elez E, Vivancos A, Hembrough T, Tabernero J, Dienstmann R, Nuciforo P.

Sci Rep. 2019 Sep 19;9(1):13568. doi: 10.1038/s41598-019-49867-7.

3.

Selective synthesis, reactivity and luminescence of unsymmetrical bis-cyclometalated Pt(iv) complexes.

Vivancos Á, Poveda D, Muñoz A, Moreno J, Bautista D, González-Herrero P.

Dalton Trans. 2019 Oct 14;48(38):14367-14382. doi: 10.1039/c9dt02431j. Epub 2019 Sep 18.

PMID:
31532408
4.

Early evolutionary divergence between papillary and anaplastic thyroid cancers.

Capdevila J, Mayor R, Mancuso FM, Iglesias C, Caratú G, Matos I, Zafón C, Hernando J, Petit A, Nuciforo P, Cameselle-Teijeiro JM, Álvarez CV, Recio JA, Tabernero J, Matias-Guiu X, Vivancos A, Seoane J.

Ann Oncol. 2019 Aug 13. pii: mdz216. doi: 10.1093/annonc/mdz216. [Epub ahead of print] No abstract available.

PMID:
31406995
5.

Long duration of immunotherapy in a STK11 mutated/KRAS wild-type non-small cell lung cancer patient.

Domingues I, Cedres S, Callejo A, Vivancos A, Martinez-Marti A, Felip E.

Pulmonology. 2019 Aug 7. pii: S2531-0437(19)30094-7. doi: 10.1016/j.pulmoe.2019.05.002. [Epub ahead of print] No abstract available.

6.

Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer.

Elez E, Chianese C, Sanz-García E, Martinelli E, Noguerido A, Mancuso FM, Caratù G, Matito J, Grasselli J, Cardone C, Esposito Abate R, Martini G, Santos C, Macarulla T, Argilés G, Capdevila J, Garcia A, Mulet N, Maiello E, Normanno N, Jones F, Tabernero J, Ciardello F, Salazar R, Vivancos A.

Mol Oncol. 2019 Sep;13(9):1827-1835. doi: 10.1002/1878-0261.12547. Epub 2019 Jul 31.

7.

Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples.

Vivancos A, Aranda E, Benavides M, Élez E, Gómez-España MA, Toledano M, Alvarez M, Parrado MRC, García-Barberán V, Diaz-Rubio E.

Sci Rep. 2019 Jun 20;9(1):8976. doi: 10.1038/s41598-019-45616-y.

8.

Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer.

Rodriguez-Freixinos V, Ruiz-Pace F, Fariñas-Madrid L, Garrido-Castro AC, Villacampa G, Nuciforo P, Vivancos A, Dienstmann R, Oaknin A.

ESMO Open. 2019 Mar 8;4(2):e000444. doi: 10.1136/esmoopen-2018-000444. eCollection 2019.

9.

Luminescent Platinum(IV) Complexes Bearing Cyclometalated 1,2,3-Triazolylidene and Bi- or Terdentate 2,6-Diarylpyridine Ligands.

Vivancos Á, Bautista D, González-Herrero P.

Chemistry. 2019 Apr 23;25(23):6014-6025. doi: 10.1002/chem.201900489. Epub 2019 Mar 29.

PMID:
30807669
10.

Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer.

García-Foncillas J, Tabernero J, Élez E, Aranda E, Benavides M, Camps C, Jantus-Lewintre E, López R, Muinelo-Romay L, Montagut C, Antón A, López G, Díaz-Rubio E, Rojo F, Vivancos A.

Br J Cancer. 2018 Dec;119(12):1464-1470. doi: 10.1038/s41416-018-0293-5. Epub 2018 Nov 23.

11.

Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings.

Bonache S, Esteban I, Moles-Fernández A, Tenés A, Duran-Lozano L, Montalban G, Bach V, Carrasco E, Gadea N, López-Fernández A, Torres-Esquius S, Mancuso F, Caratú G, Vivancos A, Tuset N, Balmaña J, Gutiérrez-Enríquez S, Diez O.

J Cancer Res Clin Oncol. 2018 Dec;144(12):2495-2513. doi: 10.1007/s00432-018-2763-9. Epub 2018 Oct 10.

PMID:
30306255
12.

Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.

Cruz C, Llop-Guevara A, Garber JE, Arun BK, Pérez Fidalgo JA, Lluch A, Telli ML, Fernández C, Kahatt C, Galmarini CM, Soto-Matos A, Alfaro V, Pérez de la Haza A, Domchek SM, Antolin S, Vahdat L, Tung NM, Lopez R, Arribas J, Vivancos A, Baselga J, Serra V, Balmaña J, Isakoff SJ.

J Clin Oncol. 2018 Nov 1;36(31):3134-3143. doi: 10.1200/JCO.2018.78.6558. Epub 2018 Sep 21. Erratum in: J Clin Oncol. 2018 Nov 20;36(33):3348. J Clin Oncol. 2019 Feb 1;37(4):362.

13.

Comparison of environmental DNA and bulk-sample metabarcoding using highly degenerate cytochrome c oxidase I primers.

Macher JN, Vivancos A, Piggott JJ, Centeno FC, Matthaei CD, Leese F.

Mol Ecol Resour. 2018 Nov;18(6):1456-1468. doi: 10.1111/1755-0998.12940. Epub 2018 Sep 9.

PMID:
30129704
14.

Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib.

Serrano C, García-Del-Muro X, Valverde C, Sebio A, Durán J, Manzano A, Pajares I, Hindi N, Landolfi S, Jiménez L, Rubió-Casadevall J, Estival A, Lavernia J, Safont MJ, Pericay C, Díaz-Beveridge R, Martínez-Marín V, Vicente-Baz D, Vivancos A, Hernández-Losa J, Arribas J, Carles J.

Oncologist. 2019 May;24(5):680-687. doi: 10.1634/theoncologist.2018-0032. Epub 2018 Aug 20.

PMID:
30126859
15.

Mesoionic and Related Less Heteroatom-Stabilized N-Heterocyclic Carbene Complexes: Synthesis, Catalysis, and Other Applications.

Vivancos Á, Segarra C, Albrecht M.

Chem Rev. 2018 Oct 10;118(19):9493-9586. doi: 10.1021/acs.chemrev.8b00148. Epub 2018 Jul 17.

PMID:
30014699
16.

TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence.

Puig I, Tenbaum SP, Chicote I, Arqués O, Martínez-Quintanilla J, Cuesta-Borrás E, Ramírez L, Gonzalo P, Soto A, Aguilar S, Eguizabal C, Caratù G, Prat A, Argilés G, Landolfi S, Casanovas O, Serra V, Villanueva A, Arroyo AG, Terracciano L, Nuciforo P, Seoane J, Recio JA, Vivancos A, Dienstmann R, Tabernero J, Palmer HG.

J Clin Invest. 2018 Aug 31;128(9):3887-3905. doi: 10.1172/JCI96393. Epub 2018 Aug 6.

17.

Early evolutionary divergence between papillary and anaplastic thyroid cancers.

Capdevila J, Mayor R, Mancuso FM, Iglesias C, Caratù G, Matos I, Zafón C, Hernando J, Petit A, Nuciforo P, Cameselle-Teijeiro JM, Álvarez CV, Recio JA, Tabernero J, Matias-Guiu X, Vivancos A, Seoane J.

Ann Oncol. 2018 Jun 1;29(6):1454-1460. doi: 10.1093/annonc/mdy123.

PMID:
29648575
18.

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.

Cruz C, Castroviejo-Bermejo M, Gutiérrez-Enríquez S, Llop-Guevara A, Ibrahim YH, Gris-Oliver A, Bonache S, Morancho B, Bruna A, Rueda OM, Lai Z, Polanska UM, Jones GN, Kristel P, de Bustos L, Guzman M, Rodríguez O, Grueso J, Montalban G, Caratú G, Mancuso F, Fasani R, Jiménez J, Howat WJ, Dougherty B, Vivancos A, Nuciforo P, Serres-Créixams X, Rubio IT, Oaknin A, Cadogan E, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Arribas J, Jonkers J, Díez O, O'Connor MJ, Balmaña J, Serra V.

Ann Oncol. 2018 May 1;29(5):1203-1210. doi: 10.1093/annonc/mdy099.

19.

Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid.

Martínez-Ricarte F, Mayor R, Martínez-Sáez E, Rubio-Pérez C, Pineda E, Cordero E, Cicuéndez M, Poca MA, López-Bigas N, Ramon Y Cajal S, Vieito M, Carles J, Tabernero J, Vivancos A, Gallego S, Graus F, Sahuquillo J, Seoane J.

Clin Cancer Res. 2018 Jun 15;24(12):2812-2819. doi: 10.1158/1078-0432.CCR-17-3800. Epub 2018 Apr 3.

20.

Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations.

Tamborero D, Rubio-Perez C, Deu-Pons J, Schroeder MP, Vivancos A, Rovira A, Tusquets I, Albanell J, Rodon J, Tabernero J, de Torres C, Dienstmann R, Gonzalez-Perez A, Lopez-Bigas N.

Genome Med. 2018 Mar 28;10(1):25. doi: 10.1186/s13073-018-0531-8.

21.

Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation.

Cedrés S, Felip E, Cruz C, Martinez de Castro A, Pardo N, Navarro A, Martinez-Marti A, Remon J, Zeron-Medina J, Balmaña J, Llop-Guevara A, Miquel JM, Sansano I, Nuciforo P, Mancuso F, Serra V, Vivancos A.

J Natl Cancer Inst. 2018 Aug 1;110(8):914-917. doi: 10.1093/jnci/djy012.

22.

Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemoradiotherapy before surgery in patients with locally advanced rectal cancer: is it ready for primetime?

Vivancos A, Élez E, Salazar R.

Ann Oncol. 2018 Mar 1;29(3):532-534. doi: 10.1093/annonc/mdy043. No abstract available.

PMID:
29401228
23.

Regional and subtype-dependent miRNA signatures in sporadic Creutzfeldt-Jakob disease are accompanied by alterations in miRNA silencing machinery and biogenesis.

Llorens F, Thüne K, Martí E, Kanata E, Dafou D, Díaz-Lucena D, Vivancos A, Shomroni O, Zafar S, Schmitz M, Michel U, Fernández-Borges N, Andréoletti O, Del Río JA, Díez J, Fischer A, Bonn S, Sklaviadis T, Torres JM, Ferrer I, Zerr I.

PLoS Pathog. 2018 Jan 22;14(1):e1006802. doi: 10.1371/journal.ppat.1006802. eCollection 2018 Jan.

24.

Genetic Profiles of Squamous Cell Carcinomas Associated with Recessive Dystrophic Epidermolysis Bullosa Unveil NOTCH and TP53 Mutations and an Increased MYC Expression.

Sans-DeSanNicolas L, Caratú G, Vidal-Cortés O, Sanchez-Redondo S, Ferrer B, Mancuso F, González-Sanchez E, Pérez-Alea M, McGrail K, Hernandez-Losa J, Bodet D, Vivancos A, Garcia-Patos V, Recio JA.

J Invest Dermatol. 2018 Jun;138(6):1423-1427. doi: 10.1016/j.jid.2017.12.026. Epub 2017 Dec 29. No abstract available.

25.

An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice.

Ellison G, Ahdesmäki M, Luke S, Waring PM, Wallace A, Wright R, Röthlisberger B, Ludin K, Merkelbach-Bruse S, Heydt C, Ligtenberg MJL, Mensenkamp AR, de Castro DG, Jones T, Vivancos A, Kondrashova O, Pauwels P, Weyn C, Hahnen E, Hauke J, Soong R, Lai Z, Dougherty B, Carr TH, Johnson J, Mills J, Barrett JC.

Hum Mutat. 2018 Mar;39(3):394-405. doi: 10.1002/humu.23375. Epub 2017 Dec 28.

26.

Unveiling the role of ancillary ligands in acceptorless benzyl alcohol dehydrogenation and etherification mediated by mesoionic carbene iridium complexes.

Vivancos Á, Petronilho A, Cardoso J, Müller-Bunz H, Albrecht M.

Dalton Trans. 2017 Dec 19;47(1):74-82. doi: 10.1039/c7dt04109h.

PMID:
29200225
27.

Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).

Martinez-Marti A, Felip E, Matito J, Mereu E, Navarro A, Cedrés S, Pardo N, Martinez de Castro A, Remon J, Miquel JM, Guillaumet-Adkins A, Nadal E, Rodriguez-Esteban G, Arqués O, Fasani R, Nuciforo P, Heyn H, Villanueva A, Palmer HG, Vivancos A.

Ann Oncol. 2017 Oct 1;28(10):2451-2457. doi: 10.1093/annonc/mdx396.

28.

Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review.

García-Foncillas J, Alba E, Aranda E, Díaz-Rubio E, López-López R, Tabernero J, Vivancos A.

Ann Oncol. 2017 Dec 1;28(12):2943-2949. doi: 10.1093/annonc/mdx501. Review.

29.

Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights.

Dienstmann R, Elez E, Argiles G, Matos I, Sanz-Garcia E, Ortiz C, Macarulla T, Capdevila J, Alsina M, Sauri T, Verdaguer H, Vilaro M, Ruiz-Pace F, Viaplana C, Garcia A, Landolfi S, Palmer HG, Nuciforo P, Rodon J, Vivancos A, Tabernero J.

Mol Oncol. 2017 Sep;11(9):1263-1272. doi: 10.1002/1878-0261.12099. Epub 2017 Jul 20.

30.

Pancreatic cancer heterogeneity and response to Mek inhibition.

Pedersen K, Bilal F, Bernadó Morales C, Salcedo MT, Macarulla T, Massó-Vallés D, Mohan V, Vivancos A, Carreras MJ, Serres X, Abu-Suboh M, Balsells J, Allende E, Sagi I, Soucek L, Tabernero J, Arribas J.

Oncogene. 2017 Oct 5;36(40):5639-5647. doi: 10.1038/onc.2017.174. Epub 2017 Jun 5.

PMID:
28581516
31.

Swiss Chemical Society Spring Meeting, University of Bern, 21st April 2017.

Byrne JP, Melle P, Valencia M, Vivancos Á.

Chimia (Aarau). 2017 May 31;71(5):316-317. doi: 10.2533/chimia.2017.316. No abstract available.

PMID:
28576164
32.

Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.

Prat A, Navarro A, Paré L, Reguart N, Galván P, Pascual T, Martínez A, Nuciforo P, Comerma L, Alos L, Pardo N, Cedrés S, Fan C, Parker JS, Gaba L, Victoria I, Viñolas N, Vivancos A, Arance A, Felip E.

Cancer Res. 2017 Jul 1;77(13):3540-3550. doi: 10.1158/0008-5472.CAN-16-3556. Epub 2017 May 9.

33.

Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.

Fernandez-Martinez A, Pascual T, Perrone G, Morales S, de la Haba J, González-Rivera M, Galván P, Zalfa F, Amato M, Gonzalez L, Prats M, Rojo F, Manso L, Paré L, Alonso I, Albanell J, Vivancos A, González A, Matito J, González S, Fernandez P, Adamo B, Muñoz M, Viladot M, Font C, Aya F, Vidal M, Caballero R, Carrasco E, Altomare V, Tonini G, Prat A, Martin M.

Oncotarget. 2017 Mar 28;8(13):21930-21937. doi: 10.18632/oncotarget.15748.

34.

Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer.

Grasselli J, Elez E, Caratù G, Matito J, Santos C, Macarulla T, Vidal J, Garcia M, Viéitez JM, Paéz D, Falcó E, Lopez Lopez C, Aranda E, Jones F, Sikri V, Nuciforo P, Fasani R, Tabernero J, Montagut C, Azuara D, Dienstmann R, Salazar R, Vivancos A.

Ann Oncol. 2017 Jun 1;28(6):1294-1301. doi: 10.1093/annonc/mdx112.

35.

Single-cell transcriptome conservation in cryopreserved cells and tissues.

Guillaumet-Adkins A, Rodríguez-Esteban G, Mereu E, Mendez-Lago M, Jaitin DA, Villanueva A, Vidal A, Martinez-Marti A, Felip E, Vivancos A, Keren-Shaul H, Heath S, Gut M, Amit I, Gut I, Heyn H.

Genome Biol. 2017 Mar 1;18(1):45. doi: 10.1186/s13059-017-1171-9.

36.

Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.

Duran I, Lambea J, Maroto P, González-Larriba JL, Flores L, Granados-Principal S, Graupera M, Sáez B, Vivancos A, Casanovas O.

Target Oncol. 2017 Feb;12(1):19-35. doi: 10.1007/s11523-016-0463-4. Review.

PMID:
27844272
37.

Genetic profile of GNAQ-mutated blue melanocytic neoplasms reveals mutations in genes linked to genomic instability and the PI3K pathway.

Pérez-Alea M, Vivancos A, Caratú G, Matito J, Ferrer B, Hernandez-Losa J, Cortés J, Muñoz E, Garcia-Patos V, Recio JA.

Oncotarget. 2016 May 10;7(19):28086-95. doi: 10.18632/oncotarget.8578.

38.

Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology.

Ibarrola-Villava M, Fleitas T, Llorca-Cardeñosa MJ, Mongort C, Alonso E, Navarro S, Burgues O, Vivancos A, Cejalvo JM, Perez-Fidalgo JA, Roselló S, Ribas G, Cervantes A.

Oncotarget. 2016 Apr 19;7(16):22543-55. doi: 10.18632/oncotarget.8002.

39.

Spatiotemporal Control of Forkhead Binding to DNA Regulates the Meiotic Gene Expression Program.

Alves-Rodrigues I, Ferreira PG, Moldón A, Vivancos AP, Hidalgo E, Guigó R, Ayté J.

Cell Rep. 2016 Feb 2;14(4):885-895. doi: 10.1016/j.celrep.2015.12.074. Epub 2016 Jan 21.

40.

Genetic evolution of nevus of Ota reveals clonal heterogeneity acquiring BAP1 and TP53 mutations.

Vivancos A, Caratú G, Matito J, Muñoz E, Ferrer B, Hernández-Losa J, Bodet D, Pérez-Alea M, Cortés J, Garcia-Patos V, Recio JA.

Pigment Cell Melanoma Res. 2016 Mar;29(2):247-53. doi: 10.1111/pcmr.12452.

PMID:
26701415
41.

Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma.

De Mattos-Arruda L, Mayor R, Ng CKY, Weigelt B, Martínez-Ricarte F, Torrejon D, Oliveira M, Arias A, Raventos C, Tang J, Guerini-Rocco E, Martínez-Sáez E, Lois S, Marín O, de la Cruz X, Piscuoglio S, Towers R, Vivancos A, Peg V, Ramon y Cajal S, Carles J, Rodon J, González-Cao M, Tabernero J, Felip E, Sahuquillo J, Berger MF, Cortes J, Reis-Filho JS, Seoane J.

Nat Commun. 2015 Nov 10;6:8839. doi: 10.1038/ncomms9839.

42.

MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.

García-García C, Rivas MA, Ibrahim YH, Calvo MT, Gris-Oliver A, Rodríguez O, Grueso J, Antón P, Guzmán M, Aura C, Nuciforo P, Jessen K, Argilés G, Dienstmann R, Bertotti A, Trusolino L, Matito J, Vivancos A, Chicote I, Palmer HG, Tabernero J, Scaltriti M, Baselga J, Serra V.

Clin Cancer Res. 2015 Dec 15;21(24):5499-5510. doi: 10.1158/1078-0432.CCR-14-3091. Epub 2015 Aug 13. Erratum in: Clin Cancer Res. 2016 Aug 1;22(15):3982.

43.

Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.

Arqués O, Chicote I, Puig I, Tenbaum SP, Argilés G, Dienstmann R, Fernández N, Caratù G, Matito J, Silberschmidt D, Rodon J, Landolfi S, Prat A, Espín E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Palmer HG.

Clin Cancer Res. 2016 Feb 1;22(3):644-56. doi: 10.1158/1078-0432.CCR-14-3081. Epub 2015 Jul 29.

44.

Identification of somatic gene mutations in penile squamous cell carcinoma.

Ferrándiz-Pulido C, Hernández-Losa J, Masferrer E, Vivancos A, Somoza R, Marés R, Valverde C, Salvador C, Placer J, Morote J, Pujol RM, Ramon y Cajal S, de Torres I, Toll A, García-Patos V.

Genes Chromosomes Cancer. 2015 Oct;54(10):629-37. doi: 10.1002/gcc.22274. Epub 2015 Jul 27.

PMID:
26216163
45.

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, Ercan D, Matthews SE, Cantarini M, Barrett JC, Jänne PA, Oxnard GR.

Nat Med. 2015 Jun;21(6):560-2. doi: 10.1038/nm.3854. Epub 2015 May 4.

46.

A Diels-Alder reaction triggered by a [4 + 3] metallacycloaddition.

Vivancos Á, Vattier F, López-Serrano J, Paneque M, Poveda ML, Álvarez E.

J Am Chem Soc. 2015 Apr 1;137(12):4074-7. doi: 10.1021/jacs.5b01532. Epub 2015 Mar 23.

PMID:
25785479
47.

ERRATUM: Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity.

Prat A, Adamo B, Fan C, Peg V, Vidal M, Galván P, Vivancos A, Nuciforo P, Palmer HG, Dawood S, Rodón J, Cajal SR, Campo JM, Felip E, Tabernero J, Cortés J.

Sci Rep. 2015 Feb 11;5:8179. doi: 10.1038/srep08179. No abstract available.

48.

Defining a minimal cell: essentiality of small ORFs and ncRNAs in a genome-reduced bacterium.

Lluch-Senar M, Delgado J, Chen WH, Lloréns-Rico V, O'Reilly FJ, Wodke JA, Unal EB, Yus E, Martínez S, Nichols RJ, Ferrar T, Vivancos A, Schmeisky A, Stülke J, van Noort V, Gavin AC, Bork P, Serrano L.

Mol Syst Biol. 2015 Jan 21;11(1):780. doi: 10.15252/msb.20145558.

49.

A mouse model uncovers LKB1 as an UVB-induced DNA damage sensor mediating CDKN1A (p21WAF1/CIP1) degradation.

Esteve-Puig R, Gil R, González-Sánchez E, Bech-Serra JJ, Grueso J, Hernández-Losa J, Moliné T, Canals F, Ferrer B, Cortés J, Bastian B, Ramón Y Cajal S, Martín-Caballero J, Flores JM, Vivancos A, García-Patos V, Recio JÁ.

PLoS Genet. 2014 Oct 16;10(10):e1004721. doi: 10.1371/journal.pgen.1004721. eCollection 2014 Oct.

50.

Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity.

Prat A, Adamo B, Fan C, Peg V, Vidal M, Galván P, Vivancos A, Nuciforo P, Palmer HG, Dawood S, Rodón J, Ramon y Cajal S, Del Campo JM, Felip E, Tabernero J, Cortés J.

Sci Rep. 2013 Dec 18;3:3544. doi: 10.1038/srep03544. Erratum in: Sci Rep. 2015;5:8179. Ramony Cajal, Santiago [corrected to Ramon y Cajal, Santiago].

Supplemental Content

Loading ...
Support Center